Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration
- PMID: 32107050
- DOI: 10.1016/j.tips.2020.01.006
Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration
Abstract
Attempts to develop neuroprotective treatments for neurodegenerative disorders have not yet been clinically successful. Axonal degeneration has been recognized as a predominant driver of disability and disease progression in central nervous system (CNS) diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson's disease, peripheral nervous system (PNS) disorders such as chemotherapy-induced, diabetic, and inherited neuropathies, and ocular disorders, such as glaucoma. In recent years, sterile alpha and TIR motif containing 1 (SARM1) has emerged as the first compelling axonal-specific target for therapeutic intervention. In this review, we discuss the role of axonal degeneration in neurodegenerative disorders, with a focus on SARM1 and the discovery of its intrinsic enzymatic function. Establishment of neurofilament light chain (NfL) as a reliable biomarker of axonal damage, and the availability of an ultrasensitive method for measuring NfL in plasma or serum, provide translational tools to make development of axonal protective, SARM1 inhibitors a viable approach to treat multiple neurodegenerative disorders.
Keywords: Axonal degeneration; SARM1; Wallerian degeneration; axonopathy; neurodegeneration; neuropathy.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy.Brain. 2021 Nov 29;144(10):3226-3238. doi: 10.1093/brain/awab184. Brain. 2021. PMID: 33964142 Free PMC article.
-
Emergence of SARM1 as a Potential Therapeutic Target for Wallerian-type Diseases.Cell Chem Biol. 2020 Jan 16;27(1):1-13. doi: 10.1016/j.chembiol.2019.11.002. Epub 2019 Nov 21. Cell Chem Biol. 2020. PMID: 31761689 Free PMC article. Review.
-
Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss.Acta Neuropathol Commun. 2019 Oct 28;7(1):166. doi: 10.1186/s40478-019-0800-9. Acta Neuropathol Commun. 2019. PMID: 31661035 Free PMC article.
-
Small Molecule SARM1 Inhibitors Recapitulate the SARM1-/- Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate.Cell Rep. 2021 Jan 5;34(1):108588. doi: 10.1016/j.celrep.2020.108588. Cell Rep. 2021. PMID: 33406435 Free PMC article.
-
Axon degeneration: mechanistic insights lead to therapeutic opportunities for the prevention and treatment of peripheral neuropathy.Pain. 2019 May;160 Suppl 1(Suppl 1):S17-S22. doi: 10.1097/j.pain.0000000000001528. Pain. 2019. PMID: 31008845 Free PMC article. Review.
Cited by
-
Axonal regeneration and sprouting as a potential therapeutic target for nervous system disorders.Neural Regen Res. 2021 Oct;16(10):1901-1910. doi: 10.4103/1673-5374.308077. Neural Regen Res. 2021. PMID: 33642358 Free PMC article. Review.
-
A conformation-specific nanobody targeting the nicotinamide mononucleotide-activated state of SARM1.Nat Commun. 2022 Dec 22;13(1):7898. doi: 10.1038/s41467-022-35581-y. Nat Commun. 2022. PMID: 36550129 Free PMC article.
-
The Role of Axonal Transport in Glaucoma.Int J Mol Sci. 2022 Apr 1;23(7):3935. doi: 10.3390/ijms23073935. Int J Mol Sci. 2022. PMID: 35409291 Free PMC article. Review.
-
Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.Exp Neurol. 2021 Nov;345:113842. doi: 10.1016/j.expneurol.2021.113842. Epub 2021 Aug 14. Exp Neurol. 2021. PMID: 34403688 Free PMC article.
-
Circulating Brain Injury Biomarkers: A Novel Method for Quantification of the Impact on the Brain After Tumor Surgery.Neurosurgery. 2023 Oct 1;93(4):847-856. doi: 10.1227/neu.0000000000002510. Epub 2023 May 5. Neurosurgery. 2023. PMID: 37140203 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
